NASDAQ Bio Company CEO Sells $1 Million in Shares

On April 14, 2026, Nasdaq-listed biotech company Vera Therapeutics, Inc. (NASDAQ: VERA) CEO Marshall Fordyce sold approximately 22,000 shares of Class A common stock on the open market under a pre-established Rule 10b5-1 trading plan. The shares traded in the $43–$45 range, generating roughly $1.01 million (about ₩1.3 billion). As a result, Fordyce’s direct stake declined by 8–9% to around 235,000 shares; however, his indirect holdings via trusts remain unchanged, according to the SEC filing.

The company has announced it will present at the Bank of America 2026 Healthcare Conference in Las Vegas from May 12 to 14. Its lead pipeline candidate, the IgA nephropathy treatment Atacicept, has been granted Priority Review by the U.S. Food and Drug Administration, with a target action date of July 7, 2026.

Vera Therapeutics is a late-stage clinical biotech focused on therapies for severe immune-mediated diseases. Its flagship program centers on Atacicept, a once-weekly self-administered injection that concurrently blocks key B-cell activating factors, with plans to commercialize it for IgA nephropathy and other autoimmune kidney disorders. Founder and CEO Marshall Fordyce has spearheaded the ORIGIN clinical program since the company’s inception in 2016, steadily building Vera’s leadership in the IgA nephropathy field.